The thymus is required for the ability of FTY720 to prolong skin allograft survival across different histocompatibility MHC barriers

Transplant International

Volumn 20, Issue 10, 2007, Pages 895-903

  Del Rio, María L ^a   Pabst, Oliver ^a   Ramirez, Pablo ^b   Penuelas Rivas, Giovanna ^b   Förster, Reinhold ^a   Rodriguez Barbosa, Jose Ignacio ^a,c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^c UNIVERSITY OF LEÓN   (Spain)

Author keywords

FTY720; Major histocompatibility complex (MHC) barriers; Skin transplantation; Thymus

Indexed keywords

FINGOLIMOD; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GRAFT SURVIVAL; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN ALLOGRAFT; SKIN GRAFT; THYMECTOMY; THYMUS;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; FLOW CYTOMETRY; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE AGENTS; MAJOR HISTOCOMPATIBILITY COMPLEX; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PROPYLENE GLYCOLS; SKIN TRANSPLANTATION; SPHINGOSINE; THYMUS GLAND; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 34548591247     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2007.00539.x     Document Type: Article

References (48)

1. Fujita T, Hirose R, Yoneta M, et al. Potent immunosuppressants, 2-alkyl-2-aminopropane-1,3-diols. J Med Chem 1996 39: 4451.
2. Fujita T, Hamamichi N, Kiuchi M, et al. Determination of absolute configuration and biological activity of new immunosuppressants, mycestericins D, E, F and G. J Antibiot (Tokyo) 1996 49: 846.
3. Suzuki S, Enosawa S, Kakefuda T, et al. Immunosuppressive effect of a new drug, FTY720, on lymphocyte responses in vitro and cardiac allograft survival in rats. Transpl Immunol 1996 4: 252.
4. Hwang MW, Matsumori A, Furukawa Y, et al. FTY720, a new immunosuppressant, promotes long-term graft survival and inhibits the progression of graft coronary artery disease in a murine model of cardiac transplantation. Circulation 1999 100: 1322.
5. Furukawa H, Suzuki T, Jin MB, et al. Prolongation of canine liver allograft survival by a novel immunosuppressant, FTY720: effect of monotherapy and combined treatment with conventional drugs. Transplantation 2000 69: 235.
6. Mitsusada M, Suzuki S, Kobayashi E, Enosawa S, Kakefuda T, Miyata M. Prevention of graft rejection and graft-versus-host reaction by a novel immunosuppressant, FTY720, in rat small bowel transplantation. Transpl Int 1997 10: 343.
7. Yan S, Rodriguez-Barbosa JI, Pabst O, et al. Protection of mouse small bowel allografts by FTY720 and costimulation blockade. Transplantation 2005 79: 1703.
8. Lima RS, Nogueira-Martins MF, Silva HT Jr., Pestana JO, Bueno V. FTY720 treatment prolongs skin graft survival in a completely incompatible strain combination. Transplant Proc 2004 36: 1015.
9. Sugito K, Koshinaga T, Inoue M, Ikeda T, Hagiwara N, Fukuzawa M. The effect of a novel immunosuppressant, FTY720, in mice without secondary lymphoid organs. Surg Today 2005 35: 662.
10. Yanagawa Y, Sugahara K, Kataoka H, Kawaguchi T, Masubuchi Y, Chiba K. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo. J Immunol 1998 160: 5493.
11. Chiba K, Yanagawa Y, Masubuchi Y, et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol 1998 160: 5037.
12. Kim YM, Sachs T, Asavaroengchai W, Bronson R, Sykes M. Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720. J Clin Invest 2003 111: 659.
13. Maki T, Gottschalk R, Ogawa N, Monaco AP. Prevention and cure of autoimmune diabetes in nonobese diabetic mice by continuous administration of FTY720. Transplantation 2005 79: 1051.
14. Matsuura M, Imayoshi T, Chiba K, Okumoto T. Effect of FTY720, a novel immunosuppressant, on adjuvant-induced arthritis in rats. Inflamm Res 2000 49: 404.
15. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006 355: 1124.
16. Baumruker T, Billich A, Brinkmann V. FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis. Expert Opin Investig Drugs 2007 16: 283.
17. Kieseier BC, Wiendl H, Hemmer B, Hartung HP. Treatment and treatment trials in multiple sclerosis. Curr Opin Neurol 2007 20: 286.
18. Graler MH, Goetzl EJ. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J 2004 18: 551.
19. Brinkmann V, Davis MD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002 277: 21453.
20. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004 427: 355.
21. Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002 296: 346.
22. Yagi H, Kamba R, Chiba K, et al. Immunosuppressant FTY720 inhibits thymocyte emigration. Eur J Immunol 2000 30: 1435.
23. Enosawa S, Suzuki S, Kakefuda T, Li XK, Amemiya H. Induction of selective cell death targeting on mature T-lymphocytes in rats by a novel immunosuppressant, FTY720. Immunopharmacology 1996 34: 171.
24. Suzuki S, Li XK, Enosawa S, Shinomiya T. A new immunosuppressant, FTY720, induces bcl-2-associated apoptotic cell death in human lymphocytes. Immunology 1996 89: 518.
25. Nagahara Y, Ikekita M, Shinomiya T. Immunosuppressant FTY720 induces apoptosis by direct induction of permeability transition and release of cytochrome c from mitochondria. J Immunol 2000 165: 3250.
26. Bohler T, Waiser J, Schwartz M, Dragun D, Neumayer HH, Budde K. FTY720 mediates apoptosis-independent lymphopenia in human renal allograft recipients: different effects on CD62 L+ and CCR5+ T lymphocytes. Transplantation 2004 77: 1424.
27. Bohler T, Budde K, Neumayer HH, Waiser J. Novel mediators of FTY720 in human lymphocytes. Transplantation 2005 79: 492.
28. Brinkmann V, Wilt C, Kristofic C, et al. FTY720: dissection of membrane receptor-operated, stereospecific effects on cell migration from receptor-independent antiproliferative and apoptotic effects. Transplant Proc 2001 33: 3078.
29. Pabst O, Herbrand H, Willenzon S, et al. Enhanced FTY720-mediated lymphocyte homing requires Galphai signaling and depends on beta2 and beta7 integrin. J Immunol 2006 176: 1474.
30. Henning G, Ohl L, Junt T, et al. CC chemokine receptor 7-dependent and -independent pathways for lymphocyte homing: modulation by FTY720. J Exp Med 2001 194: 75.
31. Chiba K. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol Ther 2005 108: 308.
32. Kataoka H, Sugahara K, Shimano K, et al. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell Mol Immunol 2005 2: 439.
33. Rodriguez-Barbosa JI, Zhao Y, Barth R, et al. Enhanced CD4 reconstitution by grafting neonatal porcine tissue in alternative locations is associated with donor-specific tolerance and suppression of preexisting xenoreactive t cells1. Transplantation 2001 72: 1223.
34. Rodriguez-Barbosa JI, Zhao Y, Zhao G, Ezquerra A, Sykes M. Murine CD4 T cells selected in a highly disparate xenogeneic porcine thymus graft do not show rapid decay in the absence of selecting MHC in the periphery. J Immunol 2002 169: 6697.
35. Unkeless JC. Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors. J Exp Med 1979 150: 580.
36. Auchincloss H Jr., Mayer T, Ghobrial R, Winn HJ. T-cell subsets, bm mutants, and the mechanisms of allogeneic skin graft rejection. Immunol Res 1989 8: 149.
37. Sawada T, Wu Y, Sachs DH, Iacomini J. CD4+ T cells are able to reject class I disparate allografts. Transplantation 1997 64: 335.
38. Rosen H, Alfonso C, Surh CD, McHeyzer-Williams MG. Rapid induction of medullary thymocyte phenotypic maturation and egress inhibition by nanomolar sphingosine 1-phosphate receptor agonist. Proc Natl Acad Sci USA 2003 100: 10907.
39. Zhang Q, Chen Y, Fairchild RL, Heeger PS, Valujskikh A. Lymphoid sequestration of alloreactive memory CD4 T cells promotes cardiac allograft survival. J Immunol 2006 176: 770.
40. Pinschewer DD, Ochsenbein AF, Odermatt B, Brinkmann V, Hengartner H, Zinkernagel RM. FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J Immunol 2000 164: 5761.
41. Penuelas-Rivas G, Dominguez-Perles R, Brinkmann V, et al. FTY720 inhibits TH1-mediated allogeneic humoral immune response. Transplant Proc 2005 37: 4124.
42. Han S, Zhang X, Wang G, et al. FTY720 suppresses humoral immunity by inhibiting germinal center reaction. Blood 2004 104: 4129.
43. Luo ZJ, Tanaka T, Kimura F, Miyasaka M. Analysis of the mode of action of a novel immunosuppressant FTY720 in mice. Immunopharmacology 1999 41: 199.
44. Cosmi L, Liotta F, Angeli R, et al. Th2 cells are less susceptible than Th1 cells to the suppressive activity of CD25+ regulatory thymocytes because of their responsiveness to different cytokines. Blood 2004 103: 3117.
45. Sawicka E, Dubois G, Jarai G, et al. The sphingosine 1-phosphate receptor agonist FTY720 differentially affects the sequestration of CD4+/CD25+ T-regulatory cells and enhances their functional activity. J Immunol 2005 175: 7973.
46. Chen ZK, Cobbold SP, Waldmann H, Metcalfe S. Amplification of natural regulatory immune mechanisms for transplantation tolerance. Transplantation 1996 62: 1200.
47. Calne RY. The future of organ transplantation: from the laboratory to the clinic. Philos Trans R Soc Lond B Biol Sci 2001 356: 767.
48. Massberg S, Von Andrian UH. Fingolimod and sphingosine-1-phosphate - modifiers of lymphocyte migration. N Engl J Med 2006 355: 1088.